Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells

Cancer Research

Volumn 60, Issue 20, 2000, Pages 5767-5772

  Souza, Rhonda F ^a,b   Shewmake, Kenneth ^a   Beer, David G ^c   Cryer, Byron ^a   Jon Spechler, Stuart ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLURBIPROFEN; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHORBOL 13 ACETATE 12 MYRISTATE;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER INHIBITION; CONTROLLED STUDY; ENZYME INHIBITION; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BARRETT ESOPHAGUS; CELL DIVISION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ESOPHAGEAL NEOPLASMS; FLURBIPROFEN; GENE EXPRESSION; GROWTH INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; SUBSTRATE SPECIFICITY; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0034667497     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Cancer statistics, 1997
2. Continuing climb in rates of esophageal adenocarcinoma
3. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
4. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
5. Barrett's esophagus
6. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element
7. Identification of a phorbol ester-repressible v-src-inducible gene
8. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
9. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells
10. Elevated cyclooxygenase-2 levels in Min mouse adenomas
11. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
12. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
13. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression
14. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells
15. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production
16. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
17. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
18. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
19. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
20. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
21. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
22. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
23. Expression of cyclooxygenase-2 in human gastric carcinoma
24. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
25. Cyclooxygenase-2 expression in human esophageal carcinoma
26. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure
27. Aspirin use and risk of fatal cancer
28. Aspirin, NSAIDS, and colon cancer prevention: Mechanisms?
29. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group
30. Aspirin and the risk of colorectal cancer in women
31. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
32. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis
33. Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
34. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
35. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
36. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
37. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
38. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process
39. Differential expression of Hsp27 in normal oesophagus. Barrett's metaplasia and oesophageal adenocarcinomas
40. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells
41. A simplification of the protein assay method of Lowry et al. which is more generally applicable
42. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
43. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
44. 1 delay in cells overexpressing prostaglandin endoperoxide synthase-2